393 related articles for article (PubMed ID: 21875635)
1. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.
Andrews NJ; Walker WT; Finn A; Heath PT; Collinson AC; Pollard AJ; Snape MD; Faust SN; Waight PA; Hoschler K; Sheasby L; Waddington C; Kerridge S; Chalk J; Reiner A; John T; Fletcher M; Allen R; Fineman N; Wilkins S; Casey M; Michaelis L; Oeser C; Okike I; Ladhani S; Miller E
Vaccine; 2011 Oct; 29(45):7913-9. PubMed ID: 21875635
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
Waddington CS; Walker WT; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston PE; Allen RJ; Okike I; Ladhani S; Sheasby E; Hoschler K; Andrews N; Waight P; Collinson AC; Heath PT; Finn A; Faust SN; Snape MD; Miller E; Pollard AJ
BMJ; 2010 May; 340():c2649. PubMed ID: 20508026
[TBL] [Abstract][Full Text] [Related]
3. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
[TBL] [Abstract][Full Text] [Related]
4. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.
Kosalaraksa P; Jeanfreau R; Frenette L; Drame M; Madariaga M; Innis BL; Godeaux O; Izurieta P; Vaughn DW
J Infect Dis; 2015 Mar; 211(5):801-10. PubMed ID: 25293368
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
[TBL] [Abstract][Full Text] [Related]
6. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months.
Carmona Martinez A; Salamanca de la Cueva I; Boutet P; Vanden Abeele C; Smolenov I; Devaster JM
Hum Vaccin Immunother; 2014; 10(7):1959-68. PubMed ID: 25424805
[TBL] [Abstract][Full Text] [Related]
7. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
Waddington C; Andrews N; Hoschler K; Walker W; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston P; Allen R; Okike I; Ladhani S; Sheasby E; Waight P; Collinson A; Heath P; Finn A; Faust S; Snape M; Miller E; Pollard A
Health Technol Assess; 2010 Oct; 14(46):1-130. PubMed ID: 20923610
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
10. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
Garcia-Sicilia J; Arístegui J; Omeñaca F; Carmona A; Tejedor JC; Merino JM; García-Corbeira P; Walravens K; Bambure V; Moris P; Caplanusi A; Gillard P; Dieussaert I
Hum Vaccin Immunother; 2015; 11(10):2359-69. PubMed ID: 26176592
[TBL] [Abstract][Full Text] [Related]
11. Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.
Cohet C; van der Most R; Bauchau V; Bekkat-Berkani R; Doherty TM; Schuind A; Tavares Da Silva F; Rappuoli R; Garçon N; Innis BL
Vaccine; 2019 May; 37(23):3006-3021. PubMed ID: 31031030
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age.
Izurieta P; Uy-Aragon MJ; Dramé M; Vaughn DW
Pediatr Infect Dis J; 2016 Feb; 35(2):e35-47. PubMed ID: 26551446
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.
Langley JM; Scheifele DW; Quach C; Vanderkooi OG; Ward B; McNeil S; Dobson S; Kellner JD; Kuhn S; Kollman T; MacKinnon-Cameron D; Smith B; Li Y; Halperin SA
Vaccine; 2012 May; 30(23):3389-94. PubMed ID: 22469860
[TBL] [Abstract][Full Text] [Related]
14. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers.
Madhun AS; Akselsen PE; Sjursen H; Pedersen G; Svindland S; Nøstbakken JK; Nilsen M; Mohn K; Jul-Larsen A; Smith I; Major D; Wood J; Cox RJ
Vaccine; 2010 Dec; 29(2):266-73. PubMed ID: 21034828
[TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine.
Langley JM; Frenette L; Chu L; McNeil S; Halperin S; Li P; Vaughn D
BMC Infect Dis; 2012 Oct; 12():279. PubMed ID: 23110320
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults.
Rostad CA; Atmar RL; Walter EB; Frey S; Meier JL; Sherman AC; Lai L; Tsong R; Kao CM; Raabe V; El Sahly HM; Keitel WA; Whitaker JA; Smith MJ; Schmader KE; Swamy GK; Abate G; Winokur P; Buchanan W; Cross K; Wegel A; Xu Y; Yildirim I; Kamidani S; Rouphael N; Roberts PC; Mulligan MJ; Anderson EJ
Clin Infect Dis; 2024 Jun; 78(6):1757-1768. PubMed ID: 38537255
[TBL] [Abstract][Full Text] [Related]
17. A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.
de Whalley P; Walker W; Snape MD; Oeser C; Casey M; Moulsdale P; Harrill C; Andrews N; Hoschler K; Thompson B; Jones C; Chalk J; Kerridge S; Tomlinson R; Heath PT; Finn A; Faust S; Miller E; Pollard AJ
Health Technol Assess; 2011 Dec; 15(45):v-vi, xi-xiii, 1-128. PubMed ID: 22257497
[TBL] [Abstract][Full Text] [Related]
18. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
Walker WT; Faust SN
Expert Rev Vaccines; 2010 Dec; 9(12):1385-98. PubMed ID: 21105775
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study.
Van Damme P; Arnou R; Kafeja F; Fiquet A; Richard P; Thomas S; Meghlaoui G; Samson SI; Ledesma E
BMC Infect Dis; 2010 May; 10():134. PubMed ID: 20504306
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
